Sientra develops medical devices for the aesthetic and plastic surgery markets, including an FDA-approved portfolio of Silimed®-brand silicone gel breast implants (shaped and round). The company’s product set also includes an extensive array of 510(k) products focused on reconstructive surgery and body contouring. Sientra plans to use new capital to commercialize its recently FDA-approved silicone breast implants, fund general operations and provide working capital. The company was founded in 2007 by CEO Hani Zeini and is based in Santa Barbara, CA. Following the financing, the company has raised a total of $151 million in equity capital.

Total raised

$65M

Funding rounds

1

Latest round

Series C

Latest activity

Mar 2012